[Image courtesy of Mission Bio]
Mission Bio (San Francisco) is a growth-stage company spun out of the microfluidics lab at the University of California San Francisco (UCSF) in 2014.“We have been commercial since late 2017,” said the company’s CEO, Yan Zhang, in a recent interview.
Initially focusing on oncology, Mission Bio has cast its gaze across precision medicine to cell and gene therapies. “We’re really in this incredible cross-section of oncology and cell and gene therapy,” Zhang said.
The company’s Tapestri platform can simultaneously provide:
Genotype and immunophenotype data from a single cell. Detection of copy number variants (CNV).Mission Bio has raised $110.9 million to date.
Zhang said that the company aims to “help drug developers take precision medicine to the next level.”